These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22498937)

  • 1. HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas.
    Guzzo F; Bellone S; Buza N; Hui P; Carrara L; Varughese J; Cocco E; Betti M; Todeschini P; Gasparrini S; Schwartz PE; Rutherford TJ; Angioli R; Pecorelli S; Santin AD
    Int J Gynecol Pathol; 2012 May; 31(3):211-21. PubMed ID: 22498937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.
    Raji R; Guzzo F; Carrara L; Varughese J; Cocco E; Bellone S; Betti M; Todeschini P; Gasparrini S; Ratner E; Silasi DA; Azodi M; Schwartz P; Rutherford TJ; Buza N; Pecorelli S; Santin AD
    J Exp Clin Cancer Res; 2011 Nov; 30(1):106. PubMed ID: 22075385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
    El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.
    Todeschini P; Cocco E; Bellone S; Varughese J; Lin K; Carrara L; Guzzo F; Buza N; Hui P; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2011 Oct; 105(8):1176-82. PubMed ID: 21915118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
    Mauricio D; Bellone S; Mutlu L; McNamara B; Manavella DD; Demirkiran C; Verzosa MSZ; Buza N; Hui P; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Mar; 170():38-45. PubMed ID: 36610380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
    Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
    Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
    Mamidi S; Cinci M; Hasmann M; Fehring V; Kirschfink M
    Mol Oncol; 2013 Jun; 7(3):580-94. PubMed ID: 23474221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
    Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The case for HER2/neu as a therapeutic target for gynecologic malignancies.
    Goyne HE; Cannon MJ
    Immunotherapy; 2012 Aug; 4(8):781-4. PubMed ID: 22947006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
    Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
    Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells.
    Zhao WP; Zhu B; Duan YZ; Chen ZT
    Oncol Rep; 2009 Jun; 21(6):1405-11. PubMed ID: 19424617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
    Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
    Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Castiglione F; Garbini F; Carriero C; Scarselli G; Taddei GL
    Int J Gynecol Cancer; 2006; 16(1):416-22. PubMed ID: 16445668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
    Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
    J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.